#VisualAbstract Amivantamab-lazertinib is Effective for Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. The progression-free survival between the amivantamab–lazertinib group (23.7 months) and the osimertinib group (16.6 months) had an HR 0.70. ...
1. Subcutaneous amivantamab combined with lazertinib was non-inferior to intravenous amivantamab with lazertinib in terms of efficacy in treating refractory ...
Click to read the study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. Treatment with osimertinib significantly improved progression-free survival, compared to placebo, in patients with unresectable stage III EGFR-mutated NSCLC 2. ...
1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3 months for the amivantamab–lazertinib–chemotherapy group, and 4.2 months for ...
1. Median progression-free survival was 11.4 months in the amivantamab–chemotherapy group and 6.7 months in the chemotherapy group with HR ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.